Research programme: malaria vaccines - Immunovaccine/Leidos

Drug Profile

Research programme: malaria vaccines - Immunovaccine/Leidos

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunovaccine; Leidos Holdings
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 20 Jan 2017 Preclinical trials in Malaria in Canada (unspecified route) (Immunovaccine pipeline, January 2017)
  • 23 Jun 2016 Early research in Malaria in Canada (unspecified route)
  • 23 Jun 2016 Immunovaccine and Leidos agree to co-develop vaccines against Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top